
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Remove Biologicals filter Biologicals (2)
- Complementary medicines (7) Apply Complementary medicines filter
- Remove Disinfectants/Sterilants filter Disinfectants/Sterilants (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Remove Medicinal cannabis filter Medicinal cannabis (0)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA) (2)
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Biologicals filter Biologicals
- (-) Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA)
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Disinfectants/Sterilants filter Disinfectants/Sterilants
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Medicinal cannabis filter Medicinal cannabis
Priority Review pathway for biologicals: feasibility, potential eligibility criteria and determination process
Closed on 28 March 2022
Consultation on potential regulatory options for 'export only' biologicals
Closed on 20 December 2021
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Fees and charges proposal 2021-22
Closed on 17 March 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
TGA communications and consultation processes: Online survey 2009
Closed on 21 June 2009